Abdullah Al Lawati

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Randomized Controlled Trial

Drug Administration

Top Venues

Current drug targets

Current medicinal chemistry

Current diabetes reviews

Endocrine, metabolic & immune disorders drug targets

This page only lists publications with an associated author ORCID identifier.

Publications

Khalid Al Balushi, Abdulrahman Al Hadhrami, Hamdan Al Balushi, Abdullah Al Lawati, Srijit Das
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma. Current drug targets 25 (3) (2024)
Khalid Al Balushi, Abdulrahman Al Hadhrami, Hamdan Al Balushi, Abdullah Al Lawati, Srijit Das
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma. Current drug targets 25 (3) (2024)
Alsalt Al-Busaidi, Omer Alabri, Jaifar Alomairi, Ahmed ElSharaawy, Abdullah Al Lawati, Hanan Al Lawati, Srijit Das
Gut Microbiota and Insulin Resistance: Understanding the Mechanism of Better Treatment of Type 2 Diabetes Mellitus. Current diabetes reviews (2024)
Rashid Al-Shibli, Mohammed AlSuleimani, Ibrahim Ahmed, Abdullah Al Lawati, Srijit Das
Association of MiRNA and Bone Tumors: Future Therapeutic Inroads. Current medicinal chemistry (2024)
Abdullah Al Lawati, Lubna Al Hashmi, Husain Al Aswami, Abdulrahman Al Hadhrami, Sok Kuan Wong, Srijit Das, Srinivasa Rao Sirasanagandla
Deleterious Biological Effects of Endocrine Disruptors: An Insight into Human Health Risks. Endocrine, metabolic & immune disorders drug targets (2024)
Khalid Al Balushi, Abdulrahman Al Hadhrami, Hamdan Al Balushi, Abdullah Al Lawati, Srijit Das
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma. Current drug targets 25 (3) (2024)
Hanan Al Lawati, Sara Al Busaidi, Thuraiya Al Rawahi, Abdullah Al Lawati, Ahmed Kifah, Srijit Das
Alendronate for Effective Treatment of Male Osteoporosis : An Insight. Current pharmaceutical design (2024)
Khalid Al Balushi, Abdulrahman Al Hadhrami, Hamdan Al Balushi, Srijit Das, Abdullah Al Lawati
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma. Current drug targets (2023)